Cargando…
Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates
Aggregates of therapeutic proteins have been associated with increased immunogenicity in pre-clinical models as well as in human patients. Recent studies to understand aggregates and their immunogenicity risks use artificial stress methods to induce high levels of aggregation. These methods may be l...
Autores principales: | Swanson, Michael D., Rios, Shantel, Mittal, Sarita, Soder, George, Jawa, Vibha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364768/ https://www.ncbi.nlm.nih.gov/pubmed/35967308 http://dx.doi.org/10.3389/fimmu.2022.915412 |
Ejemplares similares
-
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
por: Jawa, Vibha, et al.
Publicado: (2020) -
Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
por: Joubert, Marisa K., et al.
Publicado: (2012) -
Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates
por: Nabhan, Myriam, et al.
Publicado: (2020) -
Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023) -
The immunogenicity of human-origin therapeutic antibodies are associated with V gene usage
por: Hu, Zicheng, et al.
Publicado: (2023)